Online inquiry

IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15831MR)

This product GTTS-WQ15831MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&SSTR2 gene. The antibody can be applied in Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001050.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 6752
UniProt ID P07766; P30874
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15831MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14459MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ12522MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ8633MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ11287MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ4724MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ6881MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ14501MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ11178MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI0562
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW